文献速递类风湿关节炎

类风湿关节炎残疾医保受益者用药的种族与民族差异

Racial and ethnic differences in medication use among beneficiaries of social security disability insurance with rheumatoid arthritis.
PubMed 文献 · Semin Arthritis Rheum · 2020-07-23

研究分析2007、2011、2014年65岁以下因类风湿关节炎领取社会保障残疾保险并获医保覆盖者的用药数据,发现黑人较白人更少使用生物制剂、更多使用传统合成改善病情抗风湿药,西班牙裔较白人更多使用生物制剂,白人长期阿片类药物使用比例最高。

要点

  • 黑人较白人使用生物制剂更少、使用传统合成改善病情抗风湿药更多。
  • 西班牙裔较白人使用生物制剂更多,长期糖皮质激素差异仅2014年较低。
  • 白人长期阿片类药物使用比例每年均超过三分之二,为最高。

核心结论

  • 在65岁以下因类风湿关节炎领取社会保障残疾保险的医保受益者中,改善病情抗风湿药和长期阿片类药物的使用存在种族与民族差异。

研究设计与样本

  • 基于2007、2011、2014年医疗保险和医疗补助服务中心理赔数据的系列横断面分析,纳入65岁以下因残疾不再工作并领取社会保障残疾保险医保的类风湿关节炎患者,采用广义估计方程模型比较用药比例的种族与民族差异。

主要发现

  • 2007、2011、2014年参与者分别为12931、15033、15599人。
  • 未联用生物制剂的传统合成改善病情抗风湿药总体使用比例分别为31.1%、30.3%、29.2%,生物制剂分别为50.2%、51.7%、53.8%,长期糖皮质激素分别为37.6%、36.1%、34.4%,长期阿片类药物分别为61.1%、63.8%、63.7%。
  • 黑人较白人未联用生物制剂的传统合成改善病情抗风湿药使用校正绝对差异分别为+3.0%、+5.0%、+3.3%,生物制剂分别为-4.6%、-5.7%、-4.0%,均p<0.05。
  • 西班牙裔较白人生物制剂使用校正绝对差异分别为+7.1%、+7.3%、+7.5%,均p<0.05;长期糖皮质激素使用仅2014年较白人低4.2个百分点。
  • 白人长期阿片类药物使用比例每年均超过三分之二,为最高。

临床怎么用

  • 提示临床医生在类风湿关节炎残疾医保受益者中关注种族与民族差异对改善病情抗风湿药和长期阿片类药物使用的影响。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine racial/ethnic differences in the use of conventional synthetic or biologic disease-modifying anti-rheumatic drugs (csDMARDs or bDMARDs, respectively) and long-term glucocorticoids (GC) or opioids among beneficiaries of the Social Security Disability Insurance (SSDI) with rheumatoid arthritis (RA) and <65 years old. METHODS: Serial cross-sectional analyses of Centers for Medicare and Medicaid Services claims data (2007, 2011, and 2014) for individuals <65 years old with RA receiving SSDI Medicare and Medicaid, no longer working because they were considered disabled. Generalized estimating equation models were used to determine whether the proportion of patients who used csDMARD, bDMARD, long-term GC, and long-term opioids differed by race/ethnicity. RESULTS: There were 12,931; 15,033; and 15,599 participants in 2007, 2011, and 2014, respectively. The overall use of csDMARD without bDMARD among beneficiaries of the SSDI were 31.1%, 30.3%, and 29.2%; 50.2%, 51.7%, and 53.8% used bDMARDs; 37.6%, 36.1%, and 34.4% used long-term GC; and 61.1%, 63.8%, and 63.7% used long-term opioids in years 2007, 2011, and 2014 respectively. The use of csDMARDs without bDMARDs was higher and the use of bDMARDs was lower among Blacks compared to Whites (adjusted absolute difference: +3.0%, +5.0%, and +3.3% for csDMARDs without bDMARDs and -4.6%, -5.7%, and -4.0% for bDMARDs in 2007, 2011, and 2014, respectively; all p<0.05). The use of bDMARDs was higher among Hispanics compared to Whites (adjusted absolute difference: +7.1%, +7.3%, and +7.5% in 2007, 2011, and 2014, respectively; all p<0.05). Long-term GC use was lower among Hispanics than among Whites only in year 2014 (absolute percentage point difference of -4.2%); no other difference in long-term GC use was identified. Whites were the patients with the highest use of long-term opioids (more than two third in each calendar year). CONCLUSION: Racial and ethnic differences exists in regards to the treatment of RA among beneficiaries of the SSDI. These findings suggest that this already vulnerable population of patients with RA can also have a racial and ethnic disparity that can contribute to additional disease burden and that should be examined in order to inform future interventions or even inform future policy changes to the SSDI.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Navarro-Millán I, Rajan M, Lui GE, et al. Racial and ethnic differences in medication use among beneficiaries of social security disability insurance with rheumatoid arthritis. Semin Arthritis Rheum. 2020. PMID: 32911290. doi:10.1016/j.semarthrit.2020.07.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。